OpenLB
Open Library of Bioscience
Advanced Search
Journal of the National Comprehensive Cancer Network : JNCCN
May, 2015;13 (5): 554-86.

Hodgkin lymphoma, version 2.2015.

Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, Richard F Ambinder, Patricia Aoun, Celeste M Bello, Cecil M Benitez, Philip J Bierman, Kristie A Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I Gordon, Francisco J Hernandez-Ilizaliturri, Ephraim P Hochberg, Jiayi Huang, Patrick B Johnston, Nadia Khan, David G Maloney, Peter M Mauch, Monika Metzger, Joseph O Moore, David Morgan, Craig H Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N Winter, Joachim Yahalom, Jennifer L Burns, Hema Sundar, National comprehensive cancer network
Author Information
PMID: 25964641 DOI: 10.6004/jnccn.2015.0075

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

References

  1. J Clin Oncol. 2009 Sep 20;27(27):4548-54 [PMID: 19704068]
  2. N Engl J Med. 1998 Nov 19;339(21):1506-14 [PMID: 9819449]
  3. J Clin Oncol. 2005 Jul 20;23(21):4634-42 [PMID: 15837968]
  4. Ann Oncol. 2007 Apr;18(4):679-88 [PMID: 17307757]
  5. Ann Oncol. 2004 Dec;15(12):1798-804 [PMID: 15550585]
  6. Acta Haematol. 2004;112(3):141-7 [PMID: 15345896]
  7. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):19-30 [PMID: 17097834]
  8. Blood. 2015 Feb 19;125(8):1236-43 [PMID: 25533035]
  9. Eur J Haematol Suppl. 2005 Jul;(66):68-76 [PMID: 16007872]
  10. Ann Intern Med. 1994 Jun 1;120(11):903-12 [PMID: 8172436]
  11. Lancet. 1993 Apr 24;341(8852):1051-4 [PMID: 8096958]
  12. Cancer. 1984 Sep 1;54(5):885-94 [PMID: 6378359]
  13. J Clin Oncol. 2012 Dec 20;30(36):4508-14 [PMID: 23150698]
  14. Lancet. 2012 May 12;379(9828):1791-9 [PMID: 22480758]
  15. J Clin Oncol. 1995 Feb;13(2):396-402 [PMID: 7844600]
  16. J Clin Oncol. 2010 Sep 20;28(27):4199-206 [PMID: 20713848]
  17. Ann Oncol. 2002 Oct;13(10):1628-35 [PMID: 12377653]
  18. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):218-26 [PMID: 16169675]
  19. J Clin Oncol. 2011 May 10;29(14):1844-54 [PMID: 21482982]
  20. Ann Oncol. 2014 Aug;25(8):1622-8 [PMID: 24827123]
  21. J Clin Oncol. 2013 Feb 1;31(4):456-60 [PMID: 23248254]
  22. Br J Haematol. 2001 Apr;113(1):161-71 [PMID: 11328296]
  23. Ann Oncol. 2010 Jun;21(6):1222-1227 [PMID: 19901011]
  24. Am J Hematol. 2014 Jun;89(6):575-80 [PMID: 24493389]
  25. Leuk Lymphoma. 2010 Dec;51(12):2171-80 [PMID: 21077737]
  26. J Clin Oncol. 2005 Dec 20;23(36):9208-18 [PMID: 16314615]
  27. Ann Intern Med. 1991 Mar 1;114(5):361-5 [PMID: 1992877]
  28. Radiat Oncol. 2014 Apr 15;9:94 [PMID: 24735767]
  29. N Engl J Med. 2010 Aug 12;363(7):640-52 [PMID: 20818855]
  30. J Clin Oncol. 2011 Nov 10;29(32):4234-42 [PMID: 21990399]
  31. J Clin Oncol. 2003 Feb 15;21(4):607-14 [PMID: 12586796]
  32. J Clin Oncol. 2002 Feb 1;20(3):630-7 [PMID: 11821442]
  33. J Clin Oncol. 2003 Oct 1;21(19):3601-8 [PMID: 12913100]
  34. Haematologica. 2012 Jun;97(6):931-6 [PMID: 22207683]
  35. Pract Radiat Oncol. 2013 Jul-Sep;3(3):216-222 [PMID: 24674367]
  36. J Clin Oncol. 2014 Apr 20;32(12):1188-94 [PMID: 24637998]
  37. J Clin Oncol. 1999 Apr;17(4):1244 [PMID: 10561185]
  38. N Engl J Med. 2010 Nov 4;363(19):1812-21 [PMID: 21047225]
  39. J Clin Oncol. 2013 Feb 20;31(6):684-91 [PMID: 23182987]
  40. Ann Intern Med. 1980 May;92(5):587-95 [PMID: 6892984]
  41. Blood. 2011 Nov 10;118(19):5119-25 [PMID: 21937701]
  42. Haematologica. 2009 Jan;94(1):146-8 [PMID: 19001284]
  43. Radiat Oncol. 2007 Jun 05;2:20 [PMID: 17547777]
  44. J Clin Oncol. 2014 Sep 20;32(27):3059-68 [PMID: 25113753]
  45. Br J Haematol. 2004 Mar;124(5):645-52 [PMID: 14871252]
  46. N Engl J Med. 1992 Nov 19;327(21):1478-84 [PMID: 1383821]
  47. Cancer Invest. 2008 May;26(4):401-6 [PMID: 18443961]
  48. N Engl J Med. 2012 Feb 2;366(5):399-408 [PMID: 22149921]
  49. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 [PMID: 25559415]
  50. J Clin Oncol. 2013 Feb 10;31(5):592-8 [PMID: 23295809]
  51. Ann Oncol. 1995 Feb;6(2):167-72 [PMID: 7786824]
  52. Ann Oncol. 1995 Jul;6(6):609-11 [PMID: 8573542]
  53. Blood. 2012 Dec 13;120(25):4913-20 [PMID: 22932799]
  54. N Engl J Med. 2011 Jul 21;365(3):203-12 [PMID: 21774708]
  55. Ann Oncol. 2012 Nov;23(11):2953-2959 [PMID: 22767583]
  56. J Clin Oncol. 2012 Mar 20;30(9):907-13 [PMID: 22271480]
  57. J Nucl Med. 2003 Aug;44(8):1225-31 [PMID: 12902411]
  58. Hematol Oncol. 2010 Dec;28(4):168-79 [PMID: 20232475]
  59. J Clin Oncol. 2009 Nov 10;27(32):5390-6 [PMID: 19738111]
  60. Ann Oncol. 2010 Jan;21(1):126-32 [PMID: 19608615]
  61. J Clin Oncol. 2004 Jan 1;22(1):62-8 [PMID: 14657226]
  62. Fertil Steril. 2009 Mar;91(3):935.e15-6 [PMID: 18951125]
  63. Blood. 2001 Feb 1;97(3):616-23 [PMID: 11157476]
  64. Cancer. 2005 Sep 1;104(5):1066-74 [PMID: 16047335]
  65. J Clin Oncol. 2010 Jul 10;28(20):3352-9 [PMID: 20498402]
  66. J Clin Oncol. 2004 Aug 1;22(15):3046-52 [PMID: 15284254]
  67. J Clin Oncol. 1995 May;13(5):1080-8 [PMID: 7537796]
  68. Ann Oncol. 1999 May;10(5):593-5 [PMID: 10416011]
  69. J Clin Oncol. 2007 Feb 10;25(5):579-86 [PMID: 17242396]
  70. Ann Oncol. 2005 Jul;16(7):1160-8 [PMID: 15939713]
  71. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):449-55 [PMID: 22386373]
  72. Am J Hematol. 2010 May;85(5):320-4 [PMID: 20229590]
  73. Am J Clin Pathol. 2000 May;113(5):688-99 [PMID: 10800402]
  74. Ann Oncol. 2010 Mar;21(3):574-581 [PMID: 19759185]
  75. J Clin Oncol. 2014 Sep 20;32(27):3048-58 [PMID: 25113771]
  76. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1522-7 [PMID: 21705151]
  77. Leuk Lymphoma. 2012 Oct;53(10):1876-81 [PMID: 22432519]
  78. Ann Oncol. 1996 Feb;7(2):151-6 [PMID: 8777171]
  79. Ann Oncol. 2009 Nov;20(11):1848-53 [PMID: 19541793]
  80. N Engl J Med. 2003 Jun 12;348(24):2386-95 [PMID: 12802024]
  81. Bone Marrow Transplant. 1997 Nov;20(9):745-52 [PMID: 9384476]
  82. Pract Radiat Oncol. 2014 May-Jun;4(3):174-180 [PMID: 24766684]
  83. J Nucl Med. 2013 May;54(5):683-90 [PMID: 23516309]
  84. Lancet. 2002 Jun 15;359(9323):2065-71 [PMID: 12086759]
  85. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33 [PMID: 20505930]
  86. J Clin Oncol. 2009 Feb 10;27(5):805-11 [PMID: 19124807]
  87. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):370-5 [PMID: 24613810]
  88. J Clin Oncol. 2012 Jan 20;30(3):291-9 [PMID: 22184372]
  89. J Clin Oncol. 2012 Jun 20;30(18):2183-9 [PMID: 22454421]
  90. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):167-74 [PMID: 20643518]
  91. Cancer. 2005 Dec 25;105(6):432-42 [PMID: 16222688]
  92. Cancer Res. 1971 Nov;31(11):1860-1 [PMID: 5121694]
  93. Cancer Chemother Pharmacol. 1990;27(2):161-3 [PMID: 2249334]
  94. Curr Oncol Rep. 2012 Oct;14(5):403-10 [PMID: 22700011]
  95. Acta Oncol. 2003;42(5-6):589-604 [PMID: 14596517]
  96. Ann Oncol. 2007 Jun;18(6):1071-9 [PMID: 17426059]
  97. Haematologica. 2014 Jun;99(6):1107-13 [PMID: 24658820]
  98. Blood. 2008 Jan 1;111(1):71-6 [PMID: 17890456]
  99. N Engl J Med. 2007 Nov 8;357(19):1916-27 [PMID: 17989384]
  100. Eur J Cancer. 2002 Apr;38(6):795-806 [PMID: 11937314]
  101. Leuk Lymphoma. 2010 Aug;51(8):1523-9 [PMID: 20578815]
  102. Ann Oncol. 2013 Apr;24(4):1044-8 [PMID: 23136225]
  103. J Clin Oncol. 2005 Mar 1;23(7):1522-9 [PMID: 15632410]
  104. J Clin Oncol. 2007 Feb 10;25(5):571-8 [PMID: 17242397]
  105. Blood. 2004 Dec 1;104(12):3483-9 [PMID: 15315964]
  106. J Clin Oncol. 2004 Jul 15;22(14):2835-41 [PMID: 15199092]
  107. Ann Oncol. 2008 Jul;19(7):1312-1319 [PMID: 18356139]
  108. J Clin Oncol. 2001 Jun 1;19(11):2905-14 [PMID: 11387364]
  109. Br J Haematol. 2009 Feb;144(4):531-7 [PMID: 19055670]
  110. Ann Oncol. 2001 Jan;12(1):29-37 [PMID: 11249046]

Grants

  1. P30 CA006973/NCI NIH HHS
  2. T32 GM007790/NIGMS NIH HHS

MeSH Term

Follow-Up Studies
Hodgkin Disease
Humans
Neoplasm Staging
Positron-Emission Tomography
Prognosis
Recurrence
Journal Article Practice Guideline

Word Cloud

Created with Highcharts 10.0.0treatmentHodgkinlymphomaHLCHL2diagnosedlong-termuncommonmalignancyinvolvinglymphnodeslymphaticsystemClassicalnodularlymphocyte-predominantmaintypesaccountsWesterncountriesChemotherapycombinedmodalitytherapyfollowedrestagingPET/CTassessresponseusingDeauvillecriteria5-pointscalestandardinitialpatientsnewlyBrentuximabvedotinCD30-directedantibody-drugconjugateproducedencouragingresultsrelapsedrefractorydiseasepotentialeffectsremainimportantconsiderationfollow-upessentialcompletionversion2015

Similar Articles

Cited By